What Alanine aminotransferase level can reveal about liver health

1. At a Glance

Alanine aminotransferase (ALT), also called serum glutamic-pyruvic transaminase (SGPT), is an enzyme concentrated inside liver cells; its leakage into blood on hepatocyte injury makes it one of the earliest lab markers of liver damage [S4].
ALT is a core component of the Liver Function Test (LFT) panel, tested via a simple blood sample [S4].
Relevant for UPSC given rising burden of viral hepatitis and MASLD (metabolic dysfunction-associated steatotic liver disease), both public-health and Health Ministry-monitored issues [S4].
Static-plus-current topic: tests basic bio-medical literacy (Prelims "Science" GS + Health governance for Mains GS-II).

The Union Health Ministry has urged citizens to monitor ALT levels as an early indicator of liver injury, reported in The Hindu's print edition dated 31 July 2026 [S4].

ALT/SGPT has long been a standard clinical biomarker; its diagnostic role has evolved alongside classification changes in liver disease — notably the renaming of non-alcoholic fatty liver disease (NAFLD) to MASLD to reflect its metabolic (obesity/diabetes-driven) origin [S4].
WHO hepatotoxicity monitoring guidance (used in TB and other drug-safety programmes) sets threshold multiples of the Upper Limit of Normal (ULN) for ALT/AST to flag drug-induced liver injury [S1].
India has seen one of the sharpest rises in MASLD prevalence globally between 2010 and 2021, per recent research syntheses [S2].

Fact	Detail	Source
Full form	Alanine aminotransferase	[S4]
Alternate name	Serum Glutamic-Pyruvic Transaminase (SGPT)	[S4]
Location in body	Predominantly liver cells; smaller amounts in muscle and heart	[S4]
Test type	Blood sample; part of Liver Function Test (LFT)	[S4]
Global liver disease deaths	~2 million/year (WHO cited in article)	[S4]
Viral hepatitis deaths (2022)	~1.3 million	[S4]
Chronic Hepatitis B carriers	~254 million globally	[S4]
Chronic Hepatitis C carriers	~50 million globally	[S4]
Key disease driven by obesity/diabetes	MASLD (formerly NAFLD)	[S4]
NAFLD prevalence in urban India	9–32%, up to ~60% in some regions	[S2]
Acute hepatitis diagnostic threshold	ALT >10x Upper Limit of Normal	[S1]
Drug-induced liver injury stop-threshold	ALT/AST >5x ULN, or >3x ULN with hepatitis symptoms	[S1]
Monitoring body (India, current news)	Union Health Ministry	[S4]

Social: Rising obesity and diabetes (lifestyle-linked) are driving MASLD burden in India, disproportionately affecting urban populations [S2][S4].
Scientific/Technological: ALT is a sensitive but non-specific marker — elevated levels can arise from muscle/cardiac sources, not just liver, necessitating further diagnostic work-up [S4]. Also, patients can have significant liver disease despite normal ALT, limiting its sole diagnostic use [S4].
Administrative/Governance: Government health advisories on routine biomarker monitoring (like ALT) reflect a preventive/early-detection public health strategy rather than treatment-only approach [S4].
Health Policy: Aligns with WHO's global push against viral hepatitis (SDG target of hepatitis elimination) given the scale of chronic HBV/HCV infections [S4].

Union Health Ministry advisory urging ALT monitoring as an early liver-injury indicator, covered in national press on 31 July 2026 [S4].
Continued research documenting India's steep MASLD prevalence rise (2010-2021 comparative period), highlighted in recent regional research-priority reviews [S2].

ALT is also known as SGPT — Serum Glutamic-Pyruvic Transaminase [S4].
ALT is found predominantly in liver cells, with smaller amounts in muscles and heart [S4].
MASLD = Metabolic dysfunction-Associated Steatotic Liver Disease, the renamed term for NAFLD (non-alcoholic fatty liver disease) [S4].
Global liver disease deaths: approximately 2 million per year (WHO) [S4].
Viral hepatitis caused an estimated 1.3 million deaths in 2022 [S4].
Approx. 254 million people live with chronic Hepatitis B globally [S4].
Approx. 50 million people live with chronic Hepatitis C globally [S4].
ALT testing is done via a blood sample and forms part of the Liver Function Test (LFT) [S4].
A normal ALT level does not rule out significant liver disease [S4].
An elevated ALT does not necessarily indicate liver disease — it can stem from muscle or cardiac tissue [S4].
WHO hepatotoxicity guidance: stop hepatotoxic drugs if ALT/AST exceed 5x ULN, or 3x ULN with symptoms [S1].
Acute hepatitis diagnostic marker: ALT >10x the Upper Limit of Normal [S1].
India's urban NAFLD/MASLD prevalence ranges from 9–32%, up to ~60% in some regions [S2].
The advisory to monitor ALT was issued by the Union Health Ministry (not ICMR or WHO directly) [S4].

GS-II: Health governance, issues relating to development and management of Social Sector/Services relating to Health.
GS-III: Science and Technology developments, health infrastructure.
Possible question stems:
"Discuss the rising burden of metabolic dysfunction-associated steatotic liver disease (MASLD) in India and suggest preventive public health strategies." (GS-II/III)
"Examine the role of early biomarker-based screening (e.g., liver enzyme tests) in India's preventive healthcare policy." (GS-II)
"Viral hepatitis remains a major global health burden despite available vaccines and treatments. Critically analyse India's response." (GS-II)

Viral Hepatitis (Hepatitis A-E) — directly linked disease category discussed alongside ALT in the article.
National Viral Hepatitis Control Programme — India's flagship hepatitis elimination scheme.
Non-Communicable Diseases (NCDs) and lifestyle diseases — obesity/diabetes link to MASLD.
WHO Global Hepatitis Elimination Goals (2030 target) — international policy framework.
Ayushman Bharat / National Health Mission — preventive screening delivery mechanisms.
Liver transplantation and organ donation policy in India — downstream clinical/administrative angle.
Universal Health Coverage (UHC) and diagnostic access — equity dimension of biomarker testing.

Confusing ALT (SGPT) with AST (SGOT) — AST is less liver-specific, found widely in other tissues.
Assuming elevated ALT always means liver disease — muscle/cardiac causes must be ruled out [S4].
Assuming normal ALT rules out liver disease — it does not; significant disease can coexist with normal ALT [S4].
Confusing MASLD with NAFLD as different diseases — MASLD is simply the updated nomenclature for the same condition [S4].
Misattributing the ALT-monitoring advisory to WHO or ICMR instead of the Union Health Ministry [S4].

[S1] WHO SEARO — Session 4: Interpretation of Liver Function Tests — https://cdn.who.int/media/docs/default-source/searo/hiv-hepatitis/training-modules/04-liver-function-tests-interpretation.pdf — (tier: 2)
[S2] MASLD: time to optimise regional research priorities (India prevalence data) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12931381/ — (tier: 3)
[S3] Unveiling the Burden of MASLD and Liver Fibrosis in India, Phenome India Study — https://www.medrxiv.org/content/10.1101/2025.10.11.25337761.full.pdf — (tier: 3)
[S4] The Hindu — "What Alanine aminotransferase level can reveal about liver health" — https://www.thehindu.com/todays-paper/2026-07-31/th_chennai/articleG7AGB143T-15752808.ece — (tier: 4)